Weaning Protocol for Cisatracurium

Assessment and Weaning Process

Cisatracurium is an intermediate-acting neuromuscular blocking agent (NMBA) that undergoes organ-independent Hofmann elimination, making it suitable for patients with renal or hepatic dysfunction 2, 3
Recovery from cisatracurium occurs within approximately 55 minutes (range: 20 to 270 minutes) after discontinuation of infusion 4
Before weaning, assess the patient's readiness using train-of-four (TOF) monitoring to evaluate the degree of neuromuscular blockade 3
Recovery of TOF ratio >0.7 typically occurs within 34-85 minutes after discontinuation of cisatracurium 3
Recovery time is not affected by renal or hepatic dysfunction due to cisatracurium's organ-independent elimination 2, 3

Patients with prolonged ICU stays may be at risk for ICU-acquired weakness, which can complicate weaning and extubation 5
Implement additional safeguards to prevent unplanned extubation during the recovery phase, as patients may begin to move before full recovery of muscle strength 4
In patients with renal or hepatic failure, cisatracurium's pharmacodynamics remain unchanged, so no special weaning protocol is required 2
After extubation, monitor for signs of residual neuromuscular blockade such as difficulty swallowing, weak cough, or respiratory distress 1
During the early post-extubation phase, perform assisted coughing maneuvers or nasal endotracheal suctioning as necessary 1
Consider non-invasive ventilation (NIV) for patients at risk of post-extubation ventilatory failure 1
Ensure adequate sedation during the weaning process to prevent patient distress and unplanned extubation 4
Avoid relying solely on clinical assessment for recovery; use objective measures like TOF monitoring whenever possible 3